Loading patent…
AssigneeHoffmann-La Roche Inc.
InventorsBjoern Bartels, Giuseppe Cecere, Luca Gobbi, Maria-Clemencia Hernandez, Roland Humm, Andrés Miguel Olivares Morales, Angélique Patiny-Adam, Valerie Runtz-Schmitt, Christian Schnider
Estimating the term…
The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
A compound selected from:
A pharmaceutical composition comprising the compound according to 1, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.
A compound 6-chloro-5-(2-fluoro-5-hydroxyphenyl)-1,7-dimethyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one, or a pharmaceutically acceptable salt thereof.
A compound (4S)-7-chloro-6-(3-fluoro-6-hydroxy-2-pyridyl)-N-isopropyl-4-methyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-carboxamide, or a pharmaceutically acceptable salt thereof.
A compound 6-[(4S)-7-chloro-1,4-dimethyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-6-yl]-5-fluoro-pyridin-2-ol, or a pharmaceutically acceptable salt thereof.
A compound 5-chloro-6-[(4S)-7-chloro-1,4-dimethyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-6-yl]pyridin-2-ol, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.